Il Minn
YOU?
Author Swipe
View article: Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging
Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging Open
In situ T cell transfection methods overcome the complexity and high costs associated with conventional chimeric antigen receptor (CAR)-T therapy. However, the in situ CAR-T cell approach operates within the patient’s complex immune enviro…
View article: Author response: ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1
Author response: ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 Open
View article: ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 Open
Nearly 30% of pancreatic ductal adenocarcinomas (PDACs) exhibit a marked overexpression of monocarboxylate transporter 1 (MCT1) offering a unique opportunity for therapy. However, biochemical inhibitors of MCT1 have proven unsuccessful in …
View article: Author response: ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1
Author response: ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 Open
View article: ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 Open
Nearly 30% of Pancreatic ductal adenocarcinoma (PDAC)s exhibit a marked overexpression of Monocarboxylate Transporter 1 (MCT1) offering a unique opportunity for therapy. However, biochemical inhibitors of MCT1 have proven unsuccessful in c…
View article: Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma
Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma Open
Introduction Renal cell carcinoma (RCC) represents cancer originating from the renal epithelium and accounts for > 90% of cancers in the kidney. Prostate-specific membrane antigen (PSMA) is overexpressed in tumor-associated neovascular …
View article: A radioligand for in vitro autoradiography of CSF1R in post-mortem CNS tissues
A radioligand for in vitro autoradiography of CSF1R in post-mortem CNS tissues Open
View article: ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 Open
Nearly 30% of pancreatic ductal adenocarcinomas (PDACs) exhibit a marked overexpression of monocarboxylate transporter 1 (MCT1) offering a unique opportunity for therapy. However, biochemical inhibitors of MCT1 have proven unsuccessful in …
View article: ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 Open
Nearly 30% of Pancreatic ductal adenocarcinoma (PDAC)s exhibit a marked overexpression of Monocarboxylate Transporter 1 (MCT1) offering a unique opportunity for therapy. However, biochemical inhibitors of MCT1 have proven unsuccessful in c…
View article: PROMER technology: A new real-time PCR tool enabling multiplex detection of point mutation with high specificity and sensitivity
PROMER technology: A new real-time PCR tool enabling multiplex detection of point mutation with high specificity and sensitivity Open
Real-time polymerase chain reaction (real-time PCR) is a powerful tool for the precise quantification of nucleic acids in various applications. In cancer management, the monitoring of circulating tumor DNA (ctDNA) from liquid biopsies can …
View article: Imaging Brain Injury in Former National Football League Players
Imaging Brain Injury in Former National Football League Players Open
Importance Pilot studies that involved early imaging of the 18 kDa translocator protein (TSPO) using positron emission tomography (PET) indicated high levels of TSPO in the brains of active or former National Football League (NFL) players.…
View article: Preclinical Evaluation of a New Series of Albumin-Binding 177Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics
Preclinical Evaluation of a New Series of Albumin-Binding 177Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics Open
Prostate-specific membrane antigen (PSMA)-based low-molecular-weight agents using beta(β)-particle-emitting radiopharmaceuticals is a new treatment paradigm for patients with metastatic castration-resistant prostate cancer. Although result…
View article: ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 Open
Nearly 30% of Pancreatic ductal adenocarcinoma (PDAC)s exhibit a marked overexpression of Monocarboxylate Transporter 1 (MCT1) offering a unique opportunity for therapy. However, biochemical inhibitors of MCT1 have proven unsuccessful in c…
View article: Supplemental Figures S1-S8 from AEG-1 Promoter–Mediated Imaging of Prostate Cancer
Supplemental Figures S1-S8 from AEG-1 Promoter–Mediated Imaging of Prostate Cancer Open
S1: Schematic maps of AEG-Prom and PEG-Prom reporter constructs S2: c-MYC protein levels analyzed in prostate cancer cell lines by western blotting using anti-MYC antibody (57-70 kDa) S3: Time course for model maturation with PC3-ML-Luc ce…
View article: Supplemental Figure Legends from AEG-1 Promoter–Mediated Imaging of Prostate Cancer
Supplemental Figure Legends from AEG-1 Promoter–Mediated Imaging of Prostate Cancer Open
Legend for Supplemental Figures S1-S8.
View article: Supplemental Figures S1-S8 from AEG-1 Promoter–Mediated Imaging of Prostate Cancer
Supplemental Figures S1-S8 from AEG-1 Promoter–Mediated Imaging of Prostate Cancer Open
S1: Schematic maps of AEG-Prom and PEG-Prom reporter constructs S2: c-MYC protein levels analyzed in prostate cancer cell lines by western blotting using anti-MYC antibody (57-70 kDa) S3: Time course for model maturation with PC3-ML-Luc ce…
View article: Data from AEG-1 Promoter–Mediated Imaging of Prostate Cancer
Data from AEG-1 Promoter–Mediated Imaging of Prostate Cancer Open
We describe a new imaging method for detecting prostate cancer, whether localized or disseminated and metastatic to soft tissues and bone. The method relies on the use of imaging reporter genes under the control of the promoter of AEG-1 (M…
View article: Data from AEG-1 Promoter–Mediated Imaging of Prostate Cancer
Data from AEG-1 Promoter–Mediated Imaging of Prostate Cancer Open
We describe a new imaging method for detecting prostate cancer, whether localized or disseminated and metastatic to soft tissues and bone. The method relies on the use of imaging reporter genes under the control of the promoter of AEG-1 (M…
View article: Supplemental Figure Legends from AEG-1 Promoter–Mediated Imaging of Prostate Cancer
Supplemental Figure Legends from AEG-1 Promoter–Mediated Imaging of Prostate Cancer Open
Legend for Supplemental Figures S1-S8.
View article: Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma
Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma Open
Hepatocellular carcinoma (HCC) develops predominantly in the inflammatory environment of a cirrhotic liver caused by hepatitis, toxin exposure, or chronic liver disease. A targeted therapeutic approach is required to enable cancer killing …
View article: A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents
A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents Open
We have synthesized a series of 10 new, PSMA-targeted, near-infrared imaging agents intended for use in vivo for fluorescence-guided surgery (FGS). Compounds were synthesized from the commercially available amine-reactive active NHS ester …
View article: A Unique Core–Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects
A Unique Core–Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects Open
The inherent instability of nucleic acids within serum and the tumor microenvironment necessitates a suitable vehicle for non-viral gene delivery to malignant lesions. A specificity-conferring mechanism is also often needed to mitigate off…
View article: Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors
Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors Open
Prostate cancer cells are characterized by a remarkably low proliferative rate and the production of high levels of prostate-specific proteases. Protein-based toxins are attractive candidates for prostate cancer therapy because they kill c…
View article: Scalable Purification of Plasmid DNA Nanoparticles by Tangential Flow Filtration for Systemic Delivery
Scalable Purification of Plasmid DNA Nanoparticles by Tangential Flow Filtration for Systemic Delivery Open
Plasmid DNA (pDNA) nanoparticles synthesized by complexation with linear polyethylenimine (lPEI) are one of the most effective non-viral gene delivery vehicles. However, the lack of scalable and reproducible production methods and the high…
View article: An Improved <sup>211</sup>At-Labeled Agent for PSMA-Targeted α-Therapy
An Improved <sup>211</sup>At-Labeled Agent for PSMA-Targeted α-Therapy Open
α-Particle emitters targeting the prostate-specific membrane antigen (PSMA) proved effective in treating patients with prostate cancer who were unresponsive to the corresponding β-particle therapy. 211At is an α-emitter that may…
View article: Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers
Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers Open
Treatment of cancers in the lung remains a critical challenge in the clinic for which gene therapy could offer valuable options. We describe an effective approach through systemic injection of engineered polymer/DNA nanoparticles that medi…
View article: A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile
A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile Open
View article: Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [<sup>111</sup>In]In‐XYIMSR‐01 for phase I regulatory approval
Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [<sup>111</sup>In]In‐XYIMSR‐01 for phase I regulatory approval Open
[ 111 In]In‐XYIMSR‐01 is a promising single‐photon emission computed tomography (SPECT) imaging agent for identification of tumors that overexpress carbonic anhydrase IX. To translate [ 111 In]In‐XYIMSR‐01 to phase I trials, we performed a…
View article: First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET
First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET Open
View article: Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer
Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer Open